Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2024

Open Access 01-12-2024 | Arterial Diseases | Research

The additive effect of metabolic syndrome on left ventricular impairment in patients with obstructive coronary artery disease assessed by 3.0 T cardiac magnetic resonance feature tracking

Authors: Chen-Yan Min, Yue Gao, Yi-Ning Jiang, Ying-Kun Guo, Ke Shi, Zhi‑Gang Yang, Yuan Li

Published in: Cardiovascular Diabetology | Issue 1/2024

Login to get access

Abstract

Background

Metabolic syndrome (MetS) can increase the risk of morbidity and mortality of cardiovascular disease and obstructive coronary artery disease (OCAD), which usually have a poor prognosis. This study aimed to explore the impact of MetS on left ventricular (LV) deformation and function in OCAD patients and investigate the independent factors of impaired LV function and deformation.

Materials and methods

A total of 121 patients with OCAD and 52 sex- and age-matched controls who underwent cardiac magnetic resonance scanning were enrolled in the study. All OCAD patients were divided into two groups: OCAD with MetS [OCAD(MetS+), n = 83] and OCAD without MetS [OCAD(MetS−), n = 38]. LV functional and global strain parameters were measured and compared among the three groups. Multivariable linear regression analyses were constructed to investigate the independent factors of LV impairment in OCAD patients. Logistic regression analysis and receiver operating characteristic (ROC) curve analysis were performed to test the prediction efficiency of MetS for LV impairment.

Results

From controls to the OCAD(MetS−) group to the OCAD(MetS+) group, LV mass (LVM) increased, and LV global function index (LVGFI) and LV global longitudinal peak strain (GLPS) decreased (all p < 0.05). Compared with the OCAD(MetS−) group, the LV GLPS declined significantly (p = 0.027), the LVM increased (p = 0.006), and the LVGFI decreased (p = 0.043) in the OCAD(MetS+) group. After adjustment for covariates in OCAD patients, MetS was an independent factor of decreased LV GLPS (β = − 0.211, p = 0.002) and increased LVM (β = 0.221, p = 0.003). The logistic multivariable regression analysis and ROC analysis showed that combined MetS improved the efficiency of predicting LV GLPS reduction (AUC = 0.88) and LVM (AUC = 0.89) increase.

Conclusions

MetS aggravated the damage of LV deformation and function in OCAD patients and was independently associated with LV deformation and impaired LV strain. Additionally, MetS increased the prediction efficiency of increased LVM and decreased LV GLPS. Early detection and intervention of MetS in patients with OCAD is of great significance.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després JP, Ndumele CE, Vijayaraghavan K, Handelsman Y, Puckrein GA, Araneta MR, et al. The CardioMetabolic health alliance: working toward a new care model for the metabolic syndrome. J Am Coll Cardiol. 2015;66(9):1050–67.PubMedCrossRef Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després JP, Ndumele CE, Vijayaraghavan K, Handelsman Y, Puckrein GA, Araneta MR, et al. The CardioMetabolic health alliance: working toward a new care model for the metabolic syndrome. J Am Coll Cardiol. 2015;66(9):1050–67.PubMedCrossRef
2.
go back to reference Naito R, Kasai T. Obstructive coronary artery disease, a common and curable but critical comorbidity in acute decompensated heart failure. Eur J Heart Fail. 2022;24(11):2150–1.PubMedCrossRef Naito R, Kasai T. Obstructive coronary artery disease, a common and curable but critical comorbidity in acute decompensated heart failure. Eur J Heart Fail. 2022;24(11):2150–1.PubMedCrossRef
3.
go back to reference Wang X, Xu W, Song Q, Zhao Z, Meng X, Xia C, Xie Y, Yang C, Jin P, Wang F. Association between the triglyceride-glucose index and severity of coronary artery disease. Cardiovasc Diabetol. 2022;21(1):168.PubMedPubMedCentralCrossRef Wang X, Xu W, Song Q, Zhao Z, Meng X, Xia C, Xie Y, Yang C, Jin P, Wang F. Association between the triglyceride-glucose index and severity of coronary artery disease. Cardiovasc Diabetol. 2022;21(1):168.PubMedPubMedCentralCrossRef
5.
go back to reference Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–50.PubMedCrossRef Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–50.PubMedCrossRef
6.
go back to reference Ramezankhani A, Azizi F, Hadaegh F. Gender differences in changes in metabolic syndrome status and its components and risk of cardiovascular disease: a longitudinal cohort study. Cardiovasc Diabetol. 2022;21(1):227.PubMedPubMedCentralCrossRef Ramezankhani A, Azizi F, Hadaegh F. Gender differences in changes in metabolic syndrome status and its components and risk of cardiovascular disease: a longitudinal cohort study. Cardiovasc Diabetol. 2022;21(1):227.PubMedPubMedCentralCrossRef
7.
go back to reference Lee HS, Kim HL, Kim MA, Oh S, Kim M, Park SM, Yoon HJ, Byun YS, Park SM, Shin MS, et al. Sex difference in the association between metabolic syndrome and obstructive coronary artery disease: analysis of data from the KoRean wOmen’s chest pain rEgistry (KoROSE). J Womens Health. 2020;29(12):1500–6.CrossRef Lee HS, Kim HL, Kim MA, Oh S, Kim M, Park SM, Yoon HJ, Byun YS, Park SM, Shin MS, et al. Sex difference in the association between metabolic syndrome and obstructive coronary artery disease: analysis of data from the KoRean wOmen’s chest pain rEgistry (KoROSE). J Womens Health. 2020;29(12):1500–6.CrossRef
8.
go back to reference Berwick ZC, Dick GM, Tune JD. Heart of the matter: coronary dysfunction in metabolic syndrome. J Mol Cell Cardiol. 2012;52(4):848–56.PubMedCrossRef Berwick ZC, Dick GM, Tune JD. Heart of the matter: coronary dysfunction in metabolic syndrome. J Mol Cell Cardiol. 2012;52(4):848–56.PubMedCrossRef
9.
go back to reference Wong ND, Nelson JC, Granston T, Bertoni AG, Blumenthal RS, Carr JJ, Guerci A, Jacobs DR Jr, Kronmal R, Liu K, et al. Metabolic syndrome, diabetes, and incidence and progression of coronary calcium: the multiethnic study of atherosclerosis study. JACC Cardiovasc Imaging. 2012;5(4):358–66.PubMedPubMedCentralCrossRef Wong ND, Nelson JC, Granston T, Bertoni AG, Blumenthal RS, Carr JJ, Guerci A, Jacobs DR Jr, Kronmal R, Liu K, et al. Metabolic syndrome, diabetes, and incidence and progression of coronary calcium: the multiethnic study of atherosclerosis study. JACC Cardiovasc Imaging. 2012;5(4):358–66.PubMedPubMedCentralCrossRef
10.
go back to reference Sechtem U, Brown D, Godo S, Lanza GA, Shimokawa H, Sidik N. Coronary microvascular dysfunction in stable ischaemic heart disease (non-obstructive coronary artery disease and obstructive coronary artery disease). Cardiovasc Res. 2020;116(4):771–86.PubMedCrossRef Sechtem U, Brown D, Godo S, Lanza GA, Shimokawa H, Sidik N. Coronary microvascular dysfunction in stable ischaemic heart disease (non-obstructive coronary artery disease and obstructive coronary artery disease). Cardiovasc Res. 2020;116(4):771–86.PubMedCrossRef
11.
go back to reference Halliday BP, Senior R, Pennell DJ. Assessing left ventricular systolic function: from ejection fraction to strain analysis. Eur Heart J. 2021;42(7):789–97.PubMedCrossRef Halliday BP, Senior R, Pennell DJ. Assessing left ventricular systolic function: from ejection fraction to strain analysis. Eur Heart J. 2021;42(7):789–97.PubMedCrossRef
12.
go back to reference DeVore AD, McNulty S, Alenezi F, Ersboll M, Vader JM, Oh JK, Lin G, Redfield MM, Lewis G, Semigran MJ, et al. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. Eur J Heart Fail. 2017;19(7):893–900.PubMedCrossRef DeVore AD, McNulty S, Alenezi F, Ersboll M, Vader JM, Oh JK, Lin G, Redfield MM, Lewis G, Semigran MJ, et al. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. Eur J Heart Fail. 2017;19(7):893–900.PubMedCrossRef
13.
go back to reference Kammerlander AA, Donà C, Nitsche C, Koschutnik M, Schönbauer R, Duca F, Zotter-Tufaro C, Binder C, Aschauer S, Beitzke D, et al. Feature tracking of global longitudinal strain by using cardiovascular MRI improves risk stratification in heart failure with preserved ejection fraction. Radiology. 2020;296(2):290–8.PubMedCrossRef Kammerlander AA, Donà C, Nitsche C, Koschutnik M, Schönbauer R, Duca F, Zotter-Tufaro C, Binder C, Aschauer S, Beitzke D, et al. Feature tracking of global longitudinal strain by using cardiovascular MRI improves risk stratification in heart failure with preserved ejection fraction. Radiology. 2020;296(2):290–8.PubMedCrossRef
14.
go back to reference Guglielmo M, Arangalage D, Bonino MA, Angelini G, Bonanni M, Pontone G, Pascale P, Leo LA, Faletra F, Schwitter J, et al. Additional value of cardiac magnetic resonance feature tracking parameters for the evaluation of the arrhythmic risk in patients with mitral valve prolapse. J Cardiovasc Magn Reson. 2023;25(1):32.PubMedPubMedCentralCrossRef Guglielmo M, Arangalage D, Bonino MA, Angelini G, Bonanni M, Pontone G, Pascale P, Leo LA, Faletra F, Schwitter J, et al. Additional value of cardiac magnetic resonance feature tracking parameters for the evaluation of the arrhythmic risk in patients with mitral valve prolapse. J Cardiovasc Magn Reson. 2023;25(1):32.PubMedPubMedCentralCrossRef
15.
go back to reference Huang S, Li Y, Shi K, Wang J, Jiang L, Gao Y, Yan WF, Yang ZG. Impact of metabolic syndrome on left ventricular deformation and myocardial energetic efficiency compared between women and men: an MRI study. J Magn Reson Imaging. 2023;57(6):1743–51.PubMedCrossRef Huang S, Li Y, Shi K, Wang J, Jiang L, Gao Y, Yan WF, Yang ZG. Impact of metabolic syndrome on left ventricular deformation and myocardial energetic efficiency compared between women and men: an MRI study. J Magn Reson Imaging. 2023;57(6):1743–51.PubMedCrossRef
16.
go back to reference Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines. Circulation. 2023;148(9):e9–119.PubMedCrossRef Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines. Circulation. 2023;148(9):e9–119.PubMedCrossRef
17.
go back to reference Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.PubMedCrossRef Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.PubMedCrossRef
18.
go back to reference Campbell DJ, Somaratne JB, Jenkins AJ, Prior DL, Yii M, Kenny JF, Newcomb AE, Schalkwijk CG, Black MJ, Kelly DJ. Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. Cardiovasc Diabetol. 2011;10:80.PubMedPubMedCentralCrossRef Campbell DJ, Somaratne JB, Jenkins AJ, Prior DL, Yii M, Kenny JF, Newcomb AE, Schalkwijk CG, Black MJ, Kelly DJ. Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. Cardiovasc Diabetol. 2011;10:80.PubMedPubMedCentralCrossRef
19.
go back to reference PongracBarlovic D, Harjutsalo V, Gordin D, Kallio M, Forsblom C, King G, Groop PH. The association of severe diabetic retinopathy with cardiovascular outcomes in long-standing type 1 diabetes: a longitudinal follow-up. Diabetes Care. 2018;41(12):2487–94.CrossRef PongracBarlovic D, Harjutsalo V, Gordin D, Kallio M, Forsblom C, King G, Groop PH. The association of severe diabetic retinopathy with cardiovascular outcomes in long-standing type 1 diabetes: a longitudinal follow-up. Diabetes Care. 2018;41(12):2487–94.CrossRef
20.
go back to reference Chamberlain JJ, Rhinehart AS, Shaefer CF Jr, Neuman A. Diagnosis and management of diabetes: synopsis of the 2016 American diabetes association standards of medical care in diabetes. Ann Intern Med. 2016;164(8):542–52.PubMedCrossRef Chamberlain JJ, Rhinehart AS, Shaefer CF Jr, Neuman A. Diagnosis and management of diabetes: synopsis of the 2016 American diabetes association standards of medical care in diabetes. Ann Intern Med. 2016;164(8):542–52.PubMedCrossRef
21.
go back to reference Rampidis GP, Benetos G, Benz DC, Giannopoulos AA, Buechel RR. A guide for Gensini score calculation. Atherosclerosis. 2019;287:181–3.PubMedCrossRef Rampidis GP, Benetos G, Benz DC, Giannopoulos AA, Buechel RR. A guide for Gensini score calculation. Atherosclerosis. 2019;287:181–3.PubMedCrossRef
22.
go back to reference Wang J, Yang ZG, Guo YK, Jiang Y, Yan WF, Qian WL, Fang H, Min CY, Li Y. Incremental effect of coronary obstruction on myocardial microvascular dysfunction in type 2 diabetes mellitus patients evaluated by first-pass perfusion CMR study. Cardiovasc Diabetol. 2023;22(1):154.PubMedPubMedCentralCrossRef Wang J, Yang ZG, Guo YK, Jiang Y, Yan WF, Qian WL, Fang H, Min CY, Li Y. Incremental effect of coronary obstruction on myocardial microvascular dysfunction in type 2 diabetes mellitus patients evaluated by first-pass perfusion CMR study. Cardiovasc Diabetol. 2023;22(1):154.PubMedPubMedCentralCrossRef
23.
go back to reference Mewton N, Opdahl A, Choi EY, Almeida AL, Kawel N, Wu CO, Burke GL, Liu S, Liu K, Bluemke DA, et al. Left ventricular global function index by magnetic resonance imaging—a novel marker for assessment of cardiac performance for the prediction of cardiovascular events: the multi-ethnic study of atherosclerosis. Hypertension. 2013;61(4):770–8.PubMedCrossRef Mewton N, Opdahl A, Choi EY, Almeida AL, Kawel N, Wu CO, Burke GL, Liu S, Liu K, Bluemke DA, et al. Left ventricular global function index by magnetic resonance imaging—a novel marker for assessment of cardiac performance for the prediction of cardiovascular events: the multi-ethnic study of atherosclerosis. Hypertension. 2013;61(4):770–8.PubMedCrossRef
24.
go back to reference Boynton SJ, Geske JB, Dispenzieri A, Syed IS, Hanson TJ, Grogan M, Araoz PA. LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis. JACC Cardiovasc Imaging. 2016;9(6):680–6.PubMedCrossRef Boynton SJ, Geske JB, Dispenzieri A, Syed IS, Hanson TJ, Grogan M, Araoz PA. LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis. JACC Cardiovasc Imaging. 2016;9(6):680–6.PubMedCrossRef
25.
go back to reference Serrano-Ferrer J, Crendal E, Walther G, Vinet A, Dutheil F, Naughton G, Lesourd B, Chapier R, Courteix D, Obert P. Effects of lifestyle intervention on left ventricular regional myocardial function in metabolic syndrome patients from the RESOLVE randomized trial. Metabolism. 2016;65(9):1350–60.PubMedCrossRef Serrano-Ferrer J, Crendal E, Walther G, Vinet A, Dutheil F, Naughton G, Lesourd B, Chapier R, Courteix D, Obert P. Effects of lifestyle intervention on left ventricular regional myocardial function in metabolic syndrome patients from the RESOLVE randomized trial. Metabolism. 2016;65(9):1350–60.PubMedCrossRef
26.
go back to reference Burroughs Peña M, Swett K, Schneiderman N, Spevack DM, Ponce SG, Talavera GA, Kansal MM, Daviglus ML, Cai J, Hurwitz BE, et al. Cardiac structure and function with and without metabolic syndrome: the echocardiographic study of Latinos (echo-SOL). BMJ Open Diabetes Res Care. 2018;6(1): e000484.PubMedPubMedCentralCrossRef Burroughs Peña M, Swett K, Schneiderman N, Spevack DM, Ponce SG, Talavera GA, Kansal MM, Daviglus ML, Cai J, Hurwitz BE, et al. Cardiac structure and function with and without metabolic syndrome: the echocardiographic study of Latinos (echo-SOL). BMJ Open Diabetes Res Care. 2018;6(1): e000484.PubMedPubMedCentralCrossRef
27.
go back to reference Labazi H, Trask AJ. Coronary microvascular disease as an early culprit in the pathophysiology of diabetes and metabolic syndrome. Pharmacol Res. 2017;123:114–21.PubMedPubMedCentralCrossRef Labazi H, Trask AJ. Coronary microvascular disease as an early culprit in the pathophysiology of diabetes and metabolic syndrome. Pharmacol Res. 2017;123:114–21.PubMedPubMedCentralCrossRef
28.
go back to reference Shi M, Han S, Klier K, Fobo G, Montrone C, Yu S, Harada M, Henning AK, Friedrich N, Bahls M, et al. Identification of candidate metabolite biomarkers for metabolic syndrome and its five components in population-based human cohorts. Cardiovasc Diabetol. 2023;22(1):141.PubMedPubMedCentralCrossRef Shi M, Han S, Klier K, Fobo G, Montrone C, Yu S, Harada M, Henning AK, Friedrich N, Bahls M, et al. Identification of candidate metabolite biomarkers for metabolic syndrome and its five components in population-based human cohorts. Cardiovasc Diabetol. 2023;22(1):141.PubMedPubMedCentralCrossRef
29.
go back to reference Liu Y, Kabakov AY, Xie A, Shi G, Singh AK, Sodha NR, Ehsan A, Usheva A, Agbortoko V, Koren G, et al. Metabolic regulation of endothelial SK channels and human coronary microvascular function. Int J Cardiol. 2020;312:1–9.PubMedPubMedCentralCrossRef Liu Y, Kabakov AY, Xie A, Shi G, Singh AK, Sodha NR, Ehsan A, Usheva A, Agbortoko V, Koren G, et al. Metabolic regulation of endothelial SK channels and human coronary microvascular function. Int J Cardiol. 2020;312:1–9.PubMedPubMedCentralCrossRef
30.
go back to reference Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O’Moore-Sullivan T, Marwick TH. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging. 2011;4(12):1239–49.PubMedCrossRef Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O’Moore-Sullivan T, Marwick TH. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging. 2011;4(12):1239–49.PubMedCrossRef
31.
go back to reference Camici PG, Tschöpe C, Di Carli MF, Rimoldi O, Van Linthout S. Coronary microvascular dysfunction in hypertrophy and heart failure. Cardiovasc Res. 2020;116(4):806–16.PubMedCrossRef Camici PG, Tschöpe C, Di Carli MF, Rimoldi O, Van Linthout S. Coronary microvascular dysfunction in hypertrophy and heart failure. Cardiovasc Res. 2020;116(4):806–16.PubMedCrossRef
32.
go back to reference Allebban Z, Gardin JM, Wong ND, Sklar SK, Bess RL, Spence MA, Pershadsingh HA. Relation of metabolic syndrome components to left ventricular mass in Mexican Americans versus non-Hispanic whites. Metabolism. 2010;59(11):1551–5.PubMedCrossRef Allebban Z, Gardin JM, Wong ND, Sklar SK, Bess RL, Spence MA, Pershadsingh HA. Relation of metabolic syndrome components to left ventricular mass in Mexican Americans versus non-Hispanic whites. Metabolism. 2010;59(11):1551–5.PubMedCrossRef
33.
go back to reference Burchfiel CM, Skelton TN, Andrew ME, Garrison RJ, Arnett DK, Jones DW, Taylor HA Jr. Metabolic syndrome and echocardiographic left ventricular mass in blacks: the atherosclerosis risk in communities (ARIC) study. Circulation. 2005;112(6):819–27.PubMedCrossRef Burchfiel CM, Skelton TN, Andrew ME, Garrison RJ, Arnett DK, Jones DW, Taylor HA Jr. Metabolic syndrome and echocardiographic left ventricular mass in blacks: the atherosclerosis risk in communities (ARIC) study. Circulation. 2005;112(6):819–27.PubMedCrossRef
34.
go back to reference Murphy MP, Hartley RC. Mitochondria as a therapeutic target for common pathologies. Nat Rev Drug Discov. 2018;17(12):865–86.PubMedCrossRef Murphy MP, Hartley RC. Mitochondria as a therapeutic target for common pathologies. Nat Rev Drug Discov. 2018;17(12):865–86.PubMedCrossRef
35.
go back to reference Li A, Zheng N, Ding X. Mitochondrial abnormalities: a hub in metabolic syndrome-related cardiac dysfunction caused by oxidative stress. Heart Fail Rev. 2022;27(4):1387–94.PubMedCrossRef Li A, Zheng N, Ding X. Mitochondrial abnormalities: a hub in metabolic syndrome-related cardiac dysfunction caused by oxidative stress. Heart Fail Rev. 2022;27(4):1387–94.PubMedCrossRef
36.
go back to reference Sanz RL, Inserra F, García Menéndez S, Mazzei L, Ferder L, Manucha W. Metabolic syndrome and cardiac remodeling due to mitochondrial oxidative stress involving gliflozins and sirtuins. Curr Hypertens Rep. 2023;25(6):91–106.PubMedCrossRef Sanz RL, Inserra F, García Menéndez S, Mazzei L, Ferder L, Manucha W. Metabolic syndrome and cardiac remodeling due to mitochondrial oxidative stress involving gliflozins and sirtuins. Curr Hypertens Rep. 2023;25(6):91–106.PubMedCrossRef
37.
go back to reference Redfors B, Chen S, Crowley A, Ben-Yehuda O, Gersh BJ, Lembo NJ, Brown WM 3rd, Banning AP, Taggart DP, Serruys PW, et al. B-type natriuretic peptide assessment in patients undergoing revascularization for left main coronary artery disease: analysis from the EXCEL trial. Circulation. 2018;138(5):469–78.PubMedCrossRef Redfors B, Chen S, Crowley A, Ben-Yehuda O, Gersh BJ, Lembo NJ, Brown WM 3rd, Banning AP, Taggart DP, Serruys PW, et al. B-type natriuretic peptide assessment in patients undergoing revascularization for left main coronary artery disease: analysis from the EXCEL trial. Circulation. 2018;138(5):469–78.PubMedCrossRef
38.
go back to reference Wang M, Su W, Chen H, Li H. The joint association of diabetes status and NT-ProBNP with adverse cardiac outcomes in patients with non-ST-segment elevation acute coronary syndrome: a prospective cohort study. Cardiovasc Diabetol. 2023;22(1):46.PubMedPubMedCentralCrossRef Wang M, Su W, Chen H, Li H. The joint association of diabetes status and NT-ProBNP with adverse cardiac outcomes in patients with non-ST-segment elevation acute coronary syndrome: a prospective cohort study. Cardiovasc Diabetol. 2023;22(1):46.PubMedPubMedCentralCrossRef
39.
go back to reference Liu T, Wu Z, Liu J, Lv Y, Li W. Metabolic syndrome and its components reduce coronary collateralization in chronic total occlusion: an observational study. Cardiovasc Diabetol. 2021;20(1):104.PubMedPubMedCentralCrossRef Liu T, Wu Z, Liu J, Lv Y, Li W. Metabolic syndrome and its components reduce coronary collateralization in chronic total occlusion: an observational study. Cardiovasc Diabetol. 2021;20(1):104.PubMedPubMedCentralCrossRef
40.
go back to reference Lim S, Shin H, Lee Y, Yoon JW, Kang SM, Choi SH, Park KS, Jang HC, Choi SI, Chun EJ. Effect of metabolic syndrome on coronary artery stenosis and plaque characteristics as assessed with 64-detector row cardiac CT. Radiology. 2011;261(2):437–45.PubMedCrossRef Lim S, Shin H, Lee Y, Yoon JW, Kang SM, Choi SH, Park KS, Jang HC, Choi SI, Chun EJ. Effect of metabolic syndrome on coronary artery stenosis and plaque characteristics as assessed with 64-detector row cardiac CT. Radiology. 2011;261(2):437–45.PubMedCrossRef
41.
go back to reference Cho YR, Ann SH, Won KB, Park GM, Kim YG, Yang DH, Kang JW, Lim TH, Kim HK, Choe J, et al. Association between insulin resistance, hyperglycemia, and coronary artery disease according to the presence of diabetes. Sci Rep. 2019;9(1):6129.PubMedPubMedCentralCrossRef Cho YR, Ann SH, Won KB, Park GM, Kim YG, Yang DH, Kang JW, Lim TH, Kim HK, Choe J, et al. Association between insulin resistance, hyperglycemia, and coronary artery disease according to the presence of diabetes. Sci Rep. 2019;9(1):6129.PubMedPubMedCentralCrossRef
42.
go back to reference Wang KY, Zheng YY, Wu TT, Ma YT, Xie X. Predictive value of Gensini score in the long-term outcomes of patients with coronary artery disease who underwent PCI. Front Cardiovasc Med. 2021;8: 778615.PubMedCrossRef Wang KY, Zheng YY, Wu TT, Ma YT, Xie X. Predictive value of Gensini score in the long-term outcomes of patients with coronary artery disease who underwent PCI. Front Cardiovasc Med. 2021;8: 778615.PubMedCrossRef
43.
go back to reference Charach L, Blatt A, Jonas M, Teodorovitz N, Haberman D, Gendelman G, Grosskopf I, George J, Charach G. Using the Gensini score to estimate severity of STEMI, NSTEMI, unstable angina, and anginal syndrome. Medicine. 2021;100(41): e27331.PubMedPubMedCentralCrossRef Charach L, Blatt A, Jonas M, Teodorovitz N, Haberman D, Gendelman G, Grosskopf I, George J, Charach G. Using the Gensini score to estimate severity of STEMI, NSTEMI, unstable angina, and anginal syndrome. Medicine. 2021;100(41): e27331.PubMedPubMedCentralCrossRef
Metadata
Title
The additive effect of metabolic syndrome on left ventricular impairment in patients with obstructive coronary artery disease assessed by 3.0 T cardiac magnetic resonance feature tracking
Authors
Chen-Yan Min
Yue Gao
Yi-Ning Jiang
Ying-Kun Guo
Ke Shi
Zhi‑Gang Yang
Yuan Li
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2024
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-024-02225-y

Other articles of this Issue 1/2024

Cardiovascular Diabetology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.